Search results
Showing 121 to 135 of 166 results for asthma
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
This evidence summary has been updated and replaced by NICE guideline NG80.
We have moved interventional procedures guidance 635 to become HealthTech guidance 494. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE interventional procedures guidance 635.
Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)
This evidence summary has been updated and replaced by NICE guideline NG80.
This guidance has been replaced by NICE technology appraisal guidance 278.
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
Mepolizumab for treating severe refractory eosinophilic asthma (TA431)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)
This evidence summary has been updated and replaced by NICE guideline NG80.
Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)
This evidence summary has been updated and replaced by NICE guideline NG80.
Community engagement: improving health and wellbeing and reducing health inequalities (NG44)
This guideline covers community engagement approaches to reduce health inequalities, ensure health and wellbeing initiatives are effective and help local authorities and health bodies meet their statutory obligations.
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.
Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)
This evidence summary has been updated and replaced by NICE guideline NG80.